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Abstract
Background: This study aims to describe the trends in and determinants of six month mortality and loss to follow up (LTFU)
during 2005–2009 in 13 outpatient clinics in Vietnam.
Method: Data were obtained from clinical records of 3,449 Vietnamese HIV/AIDS patients aged 18 years or older who
initiated ART between 1 January 2005 and 31 December 2009. Mantel-Haenszel chi-square test, log rank test were
conducted to examine the trends of baseline characteristics, six month mortality and LTFU. Cox proportional hazards
regression models were performed to compute hazard ratio (HR) and 95% Confidence Interval (CI).
Results: Though there was a declining trend, the incidence of six month mortality and LTFU remained as high as 6% and
15%, respectively. Characteristics associated with six month mortality were gender (HR females versus males 0.54, 95%CI:
0.34–0.85), years of initiation (HR 2009 versus 2005 0.54, 95%CI: 0.41–0.80), low baseline CD4 (HR 350–500 cells/mm3 versus
,50 cells/mm3 0.26, 95%CI: 0.18–0.52), low baseline BMI (one unit increase: HR 0.96, 95%CI: 0.94–0.97), co-infection with TB
(HR 1.61, 95%CI: 1.46–1.95), history of injecting drugs (HR 1.58, 95%CI: 1.31–1.78). Characteristics associated with LTFU were
younger age (one year younger: HR 0.97, 95%CI: 0.95–0.98), males (HR females versus males 0.82, 95%CI: 0.63–0.95), and
poor adherence (HR 0.55, 95%CI: 0.13–0.87).
Conclusions: To reduce early mortality, special attention is required to ensure timely access to ART services, particularly for
patients at higher risk. Patients at risk for LTFU after ART initiation should be targeted through enhancing treatment
counselling and improving patient tracing system at ART clinics.
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Introduction
Loss to follow up (LTFU) and mortality after initiation of
antiretroviral therapy (ART) are commonly used outcomes to
evaluate the effectiveness of ART and to identify opportunities
for program improvement [1–3]. Both the socio-demographic
and clinical characteristics of patients at ART initiation can
predict the rates of LTFU and mortality [1,4]. For patient
characteristics, low baseline CD4 count and TB or other co-
infections have been consistently associated with early mortality
[1,5,6], while age and baseline BMI have been associated with
early mortality in Myanmar [7] and Johannesburg [8], but not in
South Africa [1,8–10], and being male is positively associated
with LTFU in South Africa [11] and Tanzania [12] but not in
Lesotho [13].
Despite significant expansion and increased coverage of HIV
care and treatment in Vietnam, high rates of LTFU (e.g., 12% in
2009 nationwide) have been reported [14], with many deaths
being recorded in the first year following ART initiation (e.g., first
year mortality rate was 8.7 per 100 person-years) [15]. Three
studies have examined LTFU and mortality rates in patients
receiving ART. One study conducted in 27 adult and 4 paediatric
clinics (4,531 adults and 313 children) reported that while the
12 month LTFU rate in patients initiating ART in 2007–2009 was
18.8% [14], the rate was significantly lower in tertiary-level clinics
compared with secondary-level clinics, but higher in clinics serving
less than 100 patients. Another study involving 640 patients in 13
outpatient clinics in Quang Ninh province identified a number of
significant predictors of AIDS-related mortality within 15 months
of initiation to ART: being older, initiating ART at a relatively late
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clinical stage (i.e., stage III or IV), having a low baseline BMI and
a low baseline CD4 cell count [16]. This study also found that
being male and having a low BMI or CD4 cell count at baseline
were significantly associated with early mortality [17]. To date,
however, no studies have identified patient characteristics associ-
ated with LTFU or considered mortality in the first six months as
an outcome. Furthermore, having a short follow up (#3 years),
these studies could not assess the trend of these two important
outcomes.
LTFU and early mortality present key challenges in the
implementation of ART programmes. High rates of early
mortality, in particular, can reflect a high level of treatment
failure, drug resistance, or poor adherence to treatment regimens
[5,6,8]. Similarly, a high level of LTFU can be a marker of
deficiencies in treatment counselling and patient tracing system at
the ART clinic [8,18,19]. Understanding trends in, and determi-
nants of, LTFU and early mortality, therefore, is important in
optimising ART patient outcomes, especially in Vietnam where
there has been a recent and rapid up-scaling of ART services. This
study aimed to: (i) describe the trends in early mortality and LTFU
in HIV patients who initiated the treatment within the first
five years of the country’s national ART programme (2005–2009);
(ii) identify patient demographic and clinical characteristics that
predict LTFU and six month mortality.
Methods
Study design and sample size
A prospective study design was used. The complete description
of cohort participants and the selection of clinics has been
previously published [17]. Briefly, the study sample contained
3,449 adults ($18 years) who initiated ART from 1st of January,
2005 to 31st of December, 2009 in 13 outpatient clinics, located in
six provinces across different geographic regions in Vietnam.
Ethical approval was granted by the Hanoi School of Public
Health Ethical Review Board before data collection was conduct-
ed: Participants provided their written informed consent to
participate in this study. The consent forms were provided to
the patients, and signatures were obtained. This consent procedure
was approved by the Hanoi School of Public Health Ethical
Review Board.
Data collection and measurements
In the present analysis, outcome measures were deaths
occurring in the first six months of ART and patients who were
identified as LTFU during the entire follow up period. Patients
were defined as LTFU based on the patient records: if they had
started ART and were absent from the clinic for more than
three months and did not return to the clinics by the end of the
study period (30 November 2010).
Independent variables included: baseline age (expressed in
years) and gender; transmission routes (injecting drug use [IDU],
unsafe sex [USS]); baseline clinical characteristics (body mass
index [BMI], CD4 cell counts, WHO clinical stage, TB co-
infection, opportunistic infection [OI], Cotrimoxazol [CTX] use);
adherence to treatment every six months following ART initia-
tion; and the (calendar) year of ART initiation. Adherence was
designated as ‘‘Good’’ if patient had .95% self-reported
adherence rate in the previous month, and ‘‘Poor’’ if the patient
had ,95%.
Statistical analysis
Descriptive statistics were performed to derive means and
standard deviations for continuous variables (age, baseline BMI)
and to provide frequency distributions for categorical variables
(proportion of WHO stage IV, proportion of IDU, USS, gender,
baseline OI, baseline CTX, baseline TB, treatment adherence).
Difference in trend of proportion of baseline WHO stage, baseline
OI, baseline CTX, baseline TB by initiation years were assessed
by Mantel-Haenszel chi-square test. Differences in trend of
six month mortality and LTFU by initiation years were assessed
using log rank test. The relationships between baseline character-
istics and outcomes were tested using proportional hazards
regression models. Crude and adjusted hazard ratios (HR) and
95% Confidence Intervals (CI) were reported. All analyses were
performed using SAS (version 9.2).
The analysis began with univariate analysis to identify
characteristics that were likely to be associated with the outcome
(p,0.25), and these variables were subsequently fitted into the
initial multivariate Cox regression models. Among variables that
were not significantly associated with the outcome (p.0.05), the
one that was least significant (highest p value) was removed and the
model refitted with the remaining variables. This procedure was
repeated in a backward stepwise manner. In the final model, only




The current analysis involved 3,449 patients, 75% being
males, who initiated ART between 1st of January 2005 and 31st
December 2009. By the end of the study, there were a total of
18,751 person-years of follow-up (median 1.38 years, interquar-
tile range [IQR] 0.75–2.47). The mean age at baseline was
30 years old, 65% were infected through injecting drugs. After
five years of follow up, 198 (5.7%) patients have died within first
six months on ART, 530 (15.4%) patients were lost to follow up.
The descriptive information of study participants in the cohort,
the patients died in the first six months of ART, and the LTFU
are presented in Table 1.
Trends in patient clinical characteristics and outcomes
As summarised in Table 2, overall, numbers of initiation
patients increased progressively by calendar year from 105 in
2005 to 966 in 2008. In each year from 2005 (when the ART
program in Vietnam was initiated), patients were enrolled at a
less advanced clinical stage and with higher baseline CD4 cell
counts. Specifically, baseline CD4 cell counts increased from 59
cells/mm3 (SD: 45) in 2005 to 101 (SD: 86) cells/mm3 in 2009
(simple linear regression p = 0.001). The proportion of patients at
Stage IV decreased from 61% in 2005 to 39% in 2009 (Mantel-
Haenszel chi-square test p = 0.01). However, there was no
significant trend in the proportion of patients with baseline OI
(Mantel-Haenszel p = 0.43), TB co-infection (Mantel-Haenszel
p = 0.51), and baseline CTX use (Mantel-Haenszel p = 0.73). As
presented in Figure 1, between 2005 and 2009, the six month
mortality rate declined from 11.2 to 7.5 per 100 person years (log
rank test p = 0.001), and the overall LTFU decreased from 16.2
to 8.9 per 100 person years (log rank test p = 0.001).
Associations between baseline characteristics and 6-
month mortality
Table 3 shows that there is a strong association between year of
initiation and the risk of six month mortality. After adjustment for
other covariates, being enrolled in 2009 was significantly associated
with a 46% lower risk of death within the first 6 months, compared
with being initiated in 2005 (adjusted HR, 0.54, 95% CI 0.41–0.80).
Antiretroviral Therapy in Vietnam
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Also, having a baseline CD4 cell count of 200–350 cells/mm3 was
significantly associated with a 67% lower risk of death in the first
6 months after ART initiation, compared with having a baseline
CD4 count below 50 cells/mm3 (adjusted HR, 0.33, 95% CI 0.14–
0.35).
The risk of six month mortality was significantly lower for
females (adjusted HR, 0.54, 95% CI 0.34–0.85), but higher for
Table 1. Summary of baseline characteristics of PLHIV in 13 outpatient clinics in Vietnam [N = 3,449].
Characteristics
Patients who died within
six months of ART
Patients who were lost to







Baseline age years mean (SD) 29.5 (5.8) 29.2 (6.0) 30.3 (6.6)
Gender Male 141 (71.2) 426 (80.4) 2,573 (74.6)
Female 57 (28.8) 104 (19.6) 876 (25.4)
Baseline CD4 ,50 99 (50.0) 305 (57.5) 1,538 (44.6)
(cells/mm3) 50–100 72 (36.4) 82 (15.5) 503 (14.6)
100–200 20 (10.1) 87 (16.4) 649 (18.8)
200–350 1 (0.5) 38 (7.2) 320 (9.3)
350–500 0 (0.0) 10 (1.9) 53 (1.5)
.500 0 (0.0) 4 (0.8) 43 (1.2)
Missing 6 (3.0) 4 (0.8) 343 (9.9)
ART initiation year 2005 62 (31.3) 23 (4.3) 105 (3.0)
2006 47 (23.7) 123 (23.2) 497 (14.4)
2007 38 (19.2) 128 (24.2) 891 (25.8)
2008 26 (13.1) 151 (28.5) 966 (28.0)
2009 14 (7.1) 89 (16.8) 843 (24.4)
Missing 11 (5.6) 16 (3.0) 147 (4.3)
History of IDUa Yes 152 (76.8) 380 (71.7) 2,250 (65.2)
No 43 (21.7) 98 (18.5) 937 (27.2)
Missing 3 (1.5) 52 (9.8) 262 (7.6)
History of USSb Yes 78 (39.4) 124 (23.4) 1,070 (31.0)
No 107 (54.0) 358 (67.5) 2,270 (65.8)
Missing 13 (6.6) 48 (9.1) 109 (3.2)
Baseline BMIc kg/m2 13.92 (7.3) 16.33 (6.1) 16.63 (8.4)
Baseline OId Yes 128 (64.6) 364 (68.7) 1,962 (56.9)
No 49 (24.7) 134 (25.3) 1,191 (34.5)
Missing 21 (10.6) 32 (6.0) 296 (8.6)
Baseline CTXe Yes 107 (54.0) 372 (70.2) 2,115 (61.3)
No 82 (41.5) 124 (23.4) 916 (26.6)
Missing 9 (4.5) 34 (6.4) 418 (12.1)
Baseline TBf Yes 150 (75.8) 398 (75.1) 1,121 (32.5)
No 41 (20.7) 113 (21.3) 2,091 (60.6)
Missing 7 (3.5) 19 (3.6) 237 (6.9)
Baseline WHO stage Stage I 8 (4.0) 8 (1.5) 76 (2.2)
Stage II 24 (12.1) 54 (10.2) 434 (12.6)
Stage III 38 (19.2) 74 (14.0) 692 (20.1)
Stage IV 109 (55.1) 378 (71.3) 1,919(55.6)
Missing 19 (9.6) 16 (3.0) 328 (9.5)
Adherence Poor 81 (40.9) 425 (80.2) 975 (28.3)
Good 105 (53.0) 78 (14.7) 2,145 (62.2)
Missing 12 (6.1) 27 (5.1) 329 (9.5)
a: IDU: Injecting drug user, b: USS: Unsafe sex, c: BMI: Body mass index, d: OI: Opportunistic infection, e: CTX:
Cotrimoxazol use, f: TB: Tuberculosis.
doi:10.1371/journal.pone.0073181.t001
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being infected via injecting drugs (adjusted HR, 1.58, 95% CI
1.31–1.78), having TB at initiation (adjusted HR, 1.61, 95%CI
1.46–1.95), or being at a more advanced WHO clinical stage
(adjusted HR stage IV compared to stage I, 3.51, 95%CI 1.26–
9.77). Furthermore, for every unit increase in BMI, the risk of
early mortality reduced by 4% (adjusted HR, 0.96, 95% CI 0.94–
0.97).
Baseline age (for one year younger: adjusted HR 1.00, 95%CI
0.98–1.02), opportunistic infection (adjusted HR, 1.29, 95%CI
0.96–1.73), baseline Cotrimoxazol use (adjusted HR, 0.43,
95%CI 0.33–1.97), and adherence in the first six months
(adjusted HR, 0.16, 95%CI 0.06–1.28) were not significantly
associated with mortality in the first six months after ART
initiation.
Associations between patient characteristics and LTFU
In both univariate and multivariate models, younger patients
were more likely to be LTFU than older patients (for one year
younger: adjusted HR, 0.97, 95% CI 0.95–0.98). The risk of
LTFU was significantly lower for females than for males (adjusted
HR, 0.82, 95% CI 0.63–0.95), but was higher for those infected
via IDU (adjusted HR, 1.40, 95% CI 1.25–1.89) and those who
had TB at ART initiation (adjusted HR, 1.28, 95% CI 1.05–1.72).
Being enrolled in 2009 was significantly associated with a lower
risk of LTFU, compared with being enrolled in 2005 (adjusted
HR, 0.85, 95% CI 0.32–0.91). Poor adherence was also
significantly associated with LTFU in the same direction (adjusted
HR, 0.55, 95% CI 0.13–0.87).
Baseline Cotrimoxazol use (adjusted HR, 0.47, 95%CI 0.14–
1.47), baseline WHO clinical stage (adjusted HR stage IV












(n = 843) p-valuea
Baseline age years mean (SD) 28.8 (6.5) 29.3 (6.2) 30.1 (6.3) 30.9 (6.8) 30.5 (6.9) 0.37
Gender Male 87 (82.9) 380 (76.5) 680 (76.3) 688 (71.2) 613 (72.7) 0.25
Female 18 (17.1) 117 (23.5) 211 (23.7) 278 (28.8) 230 (27.3)
Baseline CD4 (cells/mm3) 59 (45) 87 (78) 91 (80) 94 (86) 101 (86) 0.00
Mean (SD)
History of IDUc Yes 76 (72.6) 324 (65.2) 655 (73.5) 679 (70.3) 542 (64.3) 0.57
No 21 (19.8) 128 (25.7) 202(22.7) 244 (25.2) 263 (31.2)
Missing 8 (7.6) 45 (9.1) 34 (3.8) 43 (4.5) 38 (4.5)
History of USSd Yes 41 (39.2) 213 (42.9) 259 (51.8) 311 (51.3) 314 (39.0) 0.32
No 55 (52.2) 256 (51.5) 605 (67.9) 626 (64.8) 507 (60.1)
Missing 9 (8.6) 28 (5.6) 27 (3.0) 29 (3.0) 22 (2.6)
Baseline BMIe kg/m2 16.0 (6.9) 16.9 (6.8) 17.2 (5.9) 18.1 (5.4) 18.2 (7.11) 0.26
Baseline OIf Yes 54 (51.2) 248 (49.9) 462 (51.8) 496 (51.3) 329 (39.0) 0.43
No 40 (38.3) 230 (46.3) 401 (45.1) 436 (45.2) 486 (57.7)
Missing 11 (10.5) 19 (3.8) 28 (3.1) 34 (3.5) 28 (3.3)
Baseline CTXg Yes 66 (63.0) 388 (78.0) 719 (80.7) 820 (84.9) 721 (85.5) 0.73
No 27 (25.6) 73 (14.8) 130 (14.6) 105 (10.9) 90 (10.7)
Missing 12 (11.4) 36 (7.2) 42 (4.7) 41 (4.2) 32 (3.8)
Baseline TBh Yes 38 (36.0) 169 (34.0) 268 (30.1) 298 (30.9) 257 (30.5) 0.51
No 53 (50.7) 296 (59.6) 575 (64.5) 625 (64.6) 548 (65.0)
Missing 14 (13.3) 32 (6.4) 48 (5.4) 43 (4.5) 38 (4.5)
Baseline WHO stage Stage IV 64 (61.0) 268 (54.0) 407 (45.7) 396 (41.0) 330 (39.1) 0.01
Other stage 29 (27.6) 191 (38.4) 445 (49.9) 533 (55.2) 480 (57.0)
Missing 12 (11.4) 38 (7.6) 39 (4.4) 37 (3.8) 33 (3.9)
Adherence Poor 32 (30.0) 139 (28.0) 276 (31.0) 213 (22.0) 143 (17.0) 0.28
Good 63 (59.5) 327 (65.8) 580 (65.1) 714 (74.0) 666 (79.0)
Missing 11 (10.5) 31 (6.2) 35 (3.9) 39 (4.0) 34 (4.0)
Six month mortalityb 11.2 (8.5–13.7) 9.9 (6.7–10.7) 9.8 (6.4–11.5) 8.7 (6.1–10.4) 7.5 (4.8–9.6) ,0.01
Overall LTFUb 16.2 (10.3–19.4) 14.1 (11.1–18.7) 13.8 (8.6–14.9) 9.8 (5.9–11.0) 7.1 (5.3–10.5) ,0.01
a: p value from simple linear regression tests were presented for baseline CD4, baseline age, and baseline BMI; p value from Mantel-Haenszel chi-square tests were presented
for gender, history of IDU, history of USS, baseline OI, baseline CTX, baseline TB, baseline WHO stage, and adherence; p value from log rank tests were presented for six month
mortality and overall LTFU.
b: Six month mortality and overall LTFU were presented as rates per 100 person years with confidence interval.
c: IDU: Injecting drug user, d: USS: Unsafe sex, e: BMI: Body mass index, f: OI: Opportunistic infection, g: CTX:
Cotrimoxazol use, h: TB: Tuberculosis.
doi:10.1371/journal.pone.0073181.t002
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versus stage 1, 3.10, 95%CI 0.98–3.92), baseline CD4 (adjusted
HR 200–350 versus ,50 cells/mm3, 0.56, 95%CI 0.28–1.12), and
baseline BMI (for one unit increase: adjusted HR, 0.97, 95%CI
0.88–1.03) were not significantly associated with LTFU over the
entire study period.
Discussion
This study is the first published report to examine determinants
of early mortality and loss to follow up among HIV patients
receiving ART in Vietnam. In this well-defined cohort, we have
identified patient characteristics that predict early mortality and
LTFU in a resource-limited setting where a rapid scaling up of the
ART programme is underway. Being male, having initiated ART
in an earlier year, having a history of IDU and being co-infected
with TB were all independently associated with a higher risk of
both 6 month mortality and LTFU. Low baseline CD4 counts and
BMI were significantly associated with early mortality, while being
younger and having poor treatment adherence were predictive of
LTFU. Baseline OI, baseline CTX did not identify patients at a
higher risk for either of the two outcomes.
Our analysis showed a declining trend in the incidence of
six month mortality and LTFU over the first five years of the
ART programme in Vietnam. While the decreased trend in
mortality rates was consistently observed in Africa [1,6,20], the
reduced LTFU rates contrasts with the findings from South
African studies [1,20]. In conjunction with the rapid scaling up of
ART treatment, the increased coverage of HIV-related services,
improved quality of ART counselling [15], and less stringent
eligible criteria to enrol patients with a less advanced HIV disease
[21] could be key explanations for these positive outcomes.
However, the six month mortality rate of 6% and the LTFU rate
of 15% were still high, compared with other low- or middle-
income countries where ART was implemented during the same
period of time. LTFU in Myanmar, for example, was only 7%
during this period [7].
Consistent with established evidence linking low baseline CD4
counts and higher risk of mortality, the present analysis showed
that a low CD4 count level at ART initiation was a strong
predictor of death within the first six months following treatment.
Given 50% of patients initiated ART when their baseline CD4 cell
count was below 50 cells/mm3, it is likely that the contribution of
late ART initiation to mortality is substantial in the study cohort.
Reasons previously identified for late initiation to ART in Vietnam
and elsewhere include barriers to voluntary counselling and testing
services, lack of routine CD4 cell count testing for newly diagnosed
patients [22], long waiting time to enter programs, and stringent
eligible criteria for ART initiation [21,22]. As Vietnam has
adopted WHO recommendations to initiate ART at a higher level
of CD4 counts, special attention is required to strengthen post-test
counselling as well as to improve CD4 count testing services, in
order to ensure all patients have timely access to ART before the
CD4 counts drop to a low level.
Positive associations between TB co-infection and early
mortality have been consistently reported [9,16]. Our observation
of a strong relationship further confirms the role of TB in early
mortality among Vietnamese HIV infected patients receiving
ART. This is of particular importance as Vietnam has a high
prevalence of TB and high proportions HIV-related deaths (e.g.,
of 40% [16]). Given that 33% of cohort participants were co-
infected with TB at ART initiation, better integration of TB and
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Six month mortality Overall LTFU
Figure 1. Trends in six month Mortality and LTFU by calendar years in 13 outpatient clinics in Vietnam (N = 3,449).
doi:10.1371/journal.pone.0073181.g001
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TB- HIV integrated services have been suggested to reduce
mortality and morbidity of both diseases in Vietnam [23,24], this
is yet to occur [25].
Poor adherence was an independent predictor for LTFU in our
analysis, which replicates findings in other countries [26–28]. The
absence of a statistically significant association between poor
adherence and early mortality is also not without precedent: a
Botswana study, for example, showed high rates of early mortality
despite a high level of ART adherence [29]. One randomized
control trial conducted in Quang Ninh province, Vietnam [16]
also found no significant relationship between treatment adher-
ence early mortality following ART initiation. The most likely
explanation for these findings is that patients enrolled in these
ART programs when their immunodeficiency was already too far
advanced to protect them against early mortality, despite their
good treatment adherence.
That 15.4% of patients were lost to follow up in the first
12 months of ART highlights that the patient tracking system in
the study clinics could be improved. Two measures have been used
to track patients through their clinical care since the inception of
ART in Vietnam: telephone or text messages via mobile phone,
and in-person field contact by peer educators or community-based
support groups [30]. However, the implementation has not been
without challenges. Available studies noted that home-based visits
are not possible for the many patients who refuse to provide
complete or accurate contact details, due to concerns over stigma
and their confidentiality [30]. Also, many patients frequently
change their residential location and thus cannot be easily tracked
over time. Telephone or text message reminders are also difficult
as many patients often change their number for the fear that their
HIV status can be disclosed to their families or relatives [31]. To
reduce LTFU, current patient tracking efforts will need critical
assessment and special efforts are required to identify effective
intervention strategies.
Our analysis indicated that patients with an IDU history were
more likely than others to be lost to follow up. This was possibly
because IDU participants feel that they have a double-stigma, not
returning the ART clinic for continuing treatment. Furthermore,
the presence of additional illness associated with injecting drugs
may detract from the time allocated for ART services as there may
be a need to attend other preventive and curative health services
such as methadone treatment, needle exchanges, or treatment of
other co-infections (i.e., hepatitis C, TB). More importantly, earlier
studies in Vietnam and elsewhere [32] [33–35] noted that most
HIV positive IDUs continue to inject drugs when they are on
ART. Craving for drugs may inhibit their ability to adhere to their
treatment schedule.
Younger age was the only demographic characteristic that
predicted LTFU. This finding is consistent with a number of
studies in Eastern, Southern, and Western Africa [36–38] [20],
although other studies reported that older age is a significant
predictor [8,39] [7]. That young age is associated with LTFU may
be explained by the fact that a large proportion of Vietnamese
HIV patients receiving ART have an IDU history [40] and most
IDUs are younger than non-IDU patients [32]. In the present
analysis, there was statistic evidence indicating that the average
age at ART initiation in the IDU group was significantly lower
than the average age in the non-IDU group (28.7 versus 30.2,
p,0.001) (data not shown).
Our study has several limitations. First, LTFU patients may
have been identified simply on the basis of persistent absence
from clinic appointments without tracing patients who have died
without notification to the clinic. A recent study in South Africa,
for example, found that 20–60% of patients LTFU have died
during the follow up [41]. This shortcoming may have
underestimated the true mortality rate among the cohort
participants. To overcome this limitation, we used nomogram
method [42] to correct mortality for LTFU, and the results are
following: (i) Kaplan-Meier estimate for mortality of patients not
lost to follow up: 5.74% (4.96, 6.52); (ii) Kaplan-Meier estimate
for mortality of patients lost to follow up: 25% (16.6, 27.5); (iii)
Estimate of overall mortality (%) for programme 8.7% (7.6, 10.0).
Second, data available for the present analysis were based on
clinical records that were entirely dependent on the discretion of
the responsible clinic staff leading to missing values in a number of
variables. However, the missing values are likely to have minor
impacts on the findings as they accounted for less than 5%.
Further, as human resource shortages were reported in many
clinics during the study period [22], it is possible that some patients
may have been erroneously classified as LTFU by clinic staff who
may already be overwhelmed with clinical duties.
Third, the definition of LTFU (no attendance within
three months of the last scheduled visit) may have resulted in
misclassification between treatment interruption and LTFU given
some patients may have returned to a clinic after three months.
Further analysis, however, showed that only 19 (0.6%) patients
returned to a clinic more than three months after their last
scheduled visit which clearly indicates that the impact of any
such misclassification on the overall findings would be minimal.
Similarly, the transfer of patients between ART clinics is unlikely
to have resulted in them being misclassified as LTFU because all
transfers require a referral letter from the old to the new clinic
and details of the transfer must be recorded in patient records.
Fourth, the quality of the services provided by outpatient clinics,
which may have a significant impact on LTFU and mortality,
were not investigated in our study. Finally, the extent to which the
findings are generalizable to all of Vietnam is unclear, given this
study comprised 13 clinics from five provinces. Despite these
shortcomings, a robust and consistent data protocol was adhered
to which would minimize coding issues.
Conclusion
Findings from this study suggest that the rapid expansion of the
national ART programme in Vietnam has produced positive
impacts. This was reflected in more patients being enrolled at
earlier clinical stages with higher baseline CD4 counts, and
decreased mortality and LTFU. However, the incidence of early
mortality and LTFU remained significant and could benefit from
further system and programmatic improvement. To reduce early
mortality, special attention is required to ensure timely access to
ART services. Loss to follow up also requires improvements after
ART initiation. People who start ART with lower adherence,
young people, and injecting drug users should be targeted through
improving treatment counselling and the patient tracing system at
ART clinics. Given that the number of HIV patients receiving
ART in Vietnam will continue to increase resulting from the less
stringent initiation criteria, additional studies are also needed to
identify effective public health and medical interventions to reduce
mortality and LTFU as well as to improve treatment outcomes,
especially for the high-risk patient groups.
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